expressed in the hematopoietic marrow, ␤ thalassemia is rationally curable by allogeneic bone marrow transplantation (BMT). The effectiveness of this treatment was demBeta thalassemia is a hereditary anemia curable by bone marrow transplantation (BMT). Class 3 patients have a onstrated more than a decade ago. 1 The largest trial reported to date is by Lucarelli et al 2 and included 697 much worse outcome with a high incidence of rejection after BMT. Adhesion molecules, including the interpatients. The authors stratified the thalassemic patients younger than 16 years of age into three risk classes progcellular adhesion molecule 1 are thought to play an essential role in the rejection process. To investigate nostic for the outcome after BMT. Results from this study showed that class 3 patients had a much worse outcome, whether increased levels of soluble intercellular adhesion molecule 1 (sICAM-1) may be predictive of with a dramatically higher incidence of rejection compared to class 1 or class 2 patients. graft rejection, the pretransplant serum concentration of sICAM-1 of 27 ␤ thalassemic patients who rejected
One adhesion pathway in man involves the ␤2 leukocyte cantly increased levels of sICAM-1 were found in the patients who subsequently rejected the graft (mean integrin LFA-1 (CD11a/CD18) and its ligand, the intercellular adhesion molecule 1 (ICAM-1/CD54). 5, 6 The (95% CI) = 490 ng/ml (440; 540) ) as compared to those with sustained engraftment (400 ng/ml (384; 415) ), (P ICAM-1 molecule is a single chain glycoprotein of 90 kDa, composed of five Ig-like extracellular domains, a hydro-= 0.004). The mean level of sICAM-1 in patients with early rejection was significantly higher than that in phobic transmembrane domain and a short cytoplasmic domain. ICAM-1 is constitutively expressed on many hempatients with late rejection (P = 0.04). This may indicate a transfusion-mediated role of sICAM-1: some ␤ thalasatopoietic and on several non-hematopoietic cell surfaces, including vascular endothelial cells, thymic and mucosal semic patients with high sICAM-1 levels, induced by the transfusion support, may remain immunologically epithelial cells, fibroblasts, dendritic cells in germinal centers and T cells in lymphoid tissues. 7 ICAM-1 may be active, despite the conditioning regimen, therefore such patients are likely to have an early graft rejection. Our induced or up-regulated by pro-inflammatory cytokines such as IFN-␥ and IFN-␣. 8, 9 Through intercellular interacfindings indicate that sICAM-1 could be a useful indicator of immune activation in polytransfused patients tions, ICAM-1 mediates granulocyte extravasion, inflammatory processes and immunologic responses. 10 Recently, with ␤ thalassemia who have a high risk of rejection. Determination of sICAM-1 has potential clinical implia soluble form of ICAM-1 (sICAM-1) has been described.
11
Rises in sICAM-1 have been associated with renal 12 and cations in predicting which patients may reject after BMT.
liver 13 allograft rejection. The aim of the present study is to investigate whether increased levels of sICAM-1 may Keywords: ICAM-1; BMT; ␤ thalassemia; rejection be predictive of graft rejection in ␤ thalassemic patients undergoing BMT.
Beta thalassemia is a hereditary anemia characterized by a deficient or absent synthesis of ␤ globin chains that form Patients and methods the adult hemoglobin molecule. Since the defect is able sandwich enzyme immunoassay kit (Medgenix Diagnostics, Fleurus, Belgium), according to the manufacturer's recommendations. Briefly, a murine moAb to human ICAM-1, precoated to the polystyrene microtiter wells, was subsequently rejected the graft. This patient population was used to capture the ICAM-1 molecule that was subcompared to a series of 68 thalassemic patients with sussequently detected with a second horseradish peroxidasetained engraftment, comparable for the characteristics listed conjugated murine moAb to a different epitope on the in Table 1 . Eighty-seven out of 95 patients were younger molecule. than 16 years, 48 were male and 76 belonged to class 3.
The values of adsorbance from each sample were then Sixty-eight patients received more than 100 transfusions plotted on a standard curve and converted to a numerical and 80 were irregularly chelated.
14 Thirty-four patients value expressed in nanograms per milliliter. The ICAM-1 were splenectomized. Positive serology for exposure to values in the 50 BM donors in the control group ranged hepatitis B, hepatitis C and cytomegalovirus was present in from 208 to 420 ng/ml (mean 312 ng/ml). The intra-assay 68, 54 and 86 patients, respectively. No patient had any coefficient of variation (CV) ranged from 2.8 to 3%; the ongoing infection or suffered from acute or chronic GVHD inter-assay CV was 3.4 to 4.5%. The minimum detectable after BMT. The two patient populations were also similar concentration was 0.3 ng/ml. regarding liver histopathology as determined by liver biopsy performed prior to BMT 16 (Table 2 ). Conditioning 
Statistics
Homogeneity of patient characteristics was tested using the 2 test. Patient groups were compared by Mann-Whitney U two-tailed test. Results were expressed as the mean with 95% confidence interval (CI). Table 1 shows the characteristics of the 95 patients studied. No significant differences between the 27 patients who rejected and the 68 patients with sustained engraftment were observed. Borderline significance values were found for patients who received more than 100 transfusions (P Table 2 ). The tained engraftment and in patients who rejected the graft within 100 days (early rejection) or after 100 days (late rejection). Vertical bars indicate six different conditioning regimens adopted were equally mean (95% CI); the Mann-Whitney U test was used to analyze differences distributed between the two patient populations (Table 3 ).
Results
between groups.
Beta thalassemic patients with sustained engraftment showed significantly higher pretransplant sICAM-1 levels (mean (95% CI) = 400 ng/ml (384; 415)) than the marrow than sera from patients with sustained engraftment. Moredonors in the control group (312 ng/ml (294; 330) P = over, patients with ␤ thalassemia have significantly higher 0.0001) (Figure 1) . pretransplant sICAM-1 levels than normal controls, compaPatients who rejected had significantly higher pretransrable for sex and age ( Figure 1 ). This may be ascribed to plant sICAM-1 levels (490 ng/ml (440; 540)) than those the recurrent allo-antigen immunological stimulation due with sustained engraftment (P = 0.004) (Figure 1 ). Patients to transfusion support in ␤ thalassemic patients. In fact, with early rejection (within 100 days) had significantly interaction between LFA-1 and ICAM-1 is essential in antihigher pretransplant sICAM-1 levels (531 ng/ml (458;
gen recognition and T cell interaction with APCs. 17, 18 604)) than those with sustained engraftment (P = 0.0001) Therefore, high sICAM-1 levels in ␤ thalassemic patients or those with late rejection (P = 0.04); no significant values may reflect immune activation following the transfusion (P = 0.27) between sICAM-1 levels of patients with late antigenic stimulus. However, elevated sICAM-1 levels are rejection and patients with sustained engraftment was found not specific for an immunological insult, since high levels ( Figure 2 ).
were also detected in patients with inflammatory complications 19 and during renal, 12,20 liver 13,21 or cardiac 22 ,23 acute rejection as well as during GVHD after BMT. 24, 25 None of Discussion the patients in this series had any ongoing infection and there were no significant differences regarding hepatitis B The results of this study demonstrate that pretransplant sera or C and cytomegalovirus IgG-positive serology between from patients with ␤ thalassemia who rejected the graft patients with sustained engraftment and patients who contain significantly higher concentrations of sICAM-1 rejected the graft (Table 1) . Liver histopathology did not reveal any substantial differences in fibrosis, siderosis and chronic hepatitis between the two patient populations (Table 2) . Even though the two patient groups are balanced for all the variables listed in Tables 1 and 2 and for the conditioning regimens adopted (Table 3) , patients with sustained engraftment were more heavily transfused than patients who rejected the graft. In fact 84% of patients with sustained engraftment had received more than 100 transfusions compared to 41% of those who rejected the graft (Table 1) . Since the report of Opelz and Terasaki 26 in the early 1970s, it is well known that pretransplant transfusions lead to an improvement of kidney allograft survival, probably due to the induction of a state of immune unresponsiveness. However, in our patient series sICAM-1 levels do not correlate with the number of blood transfusions administered (data not shown). Never- Whatever may be the mechanism leading to high noticeable that patients with early graft rejection had sig-
